50,000 patients to be tracked: how does new kidney drug work in daily life?

NCT ID NCT06278207

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 31 times

Summary

This study looks at real-world data from 50,000 people in Asia and the US who have both chronic kidney disease and type 2 diabetes and are taking the drug finerenone as part of their regular care. Researchers will collect information on patients' age, other health conditions, and medications to see how finerenone is being used and how it affects kidney and heart health. No extra visits or tests are required—only existing medical records are analyzed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Bayer
RECRUITING

Berlin, 13353, Germany
Many Locations
COMPLETED

Multiple Locations, New Jersey, 07981, United States
Many Locations
COMPLETED

Multiple Locations, Japan
Many Locations
COMPLETED

Multiple Locations, Taiwan

Conditions

Explore the condition pages connected to this study.

CHRONIC KIDNEY DISEASE TYPE 2 DIABETES MELLITUS